The FDA Just Cleared a New JUUL. That Makes 48 Approved Vapes — and Zero Approved Meth Medications.

This week the FDA authorized marketing of JUUL2, the company’s next-generation device, along with tobacco- and menthol-flavored pods at 18 mg/mL nicotine — a lower strength than the original JUUL pods the same agency approved last year. That brings the total number of FDA-authorized e-cigarette products to 48.

Every one of those 48 approvals was granted on the same theory: that helping an adult smoker switch to vaping is worth the risk of a teenager picking it up instead. The theory has never once been tested against what actually happened the last time regulators bet on it.

Here’s the plain version of the FDA’s reasoning: cigarette smoke kills roughly half of long-term users through cancer, heart disease, and lung disease; vaping delivers nicotine without burning tobacco, which the agency’s own risk-benefit framework treats as meaningfully less harmful for someone who was already smoking and switches entirely. On paper, that’s defensible harm reduction — meeting a smoker where they are instead of demanding abstinence outright. The trouble is JUUL is not a hypothetical company being asked to earn public trust for the first time. It’s the company whose original device, approved under looser 2015-era rules, became the product most closely associated with the youth vaping surge that peaked in 2019 and forced the FDA to pull flavored pods from the market in the first place. The American Lung Association’s response to this round of authorizations makes exactly this point: menthol and tobacco flavors are marketed as adult-smoker-only, but JUUL’s own product history is the reason anyone doubts that a flavor label on a nicotine device stays where the marketing says it will.

The device itself has a genuine safety feature this time — JUUL2 requires user authentication to unlock, aimed at keeping it out of a minor’s hands even if the pod flavors are appealing to one. Whether an authentication gate actually stops a 16-year-old who wants a vape, versus just adding one more step, is an empirical question nobody has answered yet with this specific device in the real world — it’s a mechanism, not a track record. The lower 18 mg/mL nicotine strength is a real, measurable step down from the original pods, and lower nicotine delivery per pod is generally better for anyone trying to taper off rather than maintain a heavy daily habit.

For providers doing intake with a patient who vapes: don’t assume the device or the flavor tells you the dose. Ask what nicotine strength is on the pod, not just the brand — a patient still using original-strength JUUL pods is getting meaningfully more nicotine per session than one who switched to this new line, and that difference matters for how you counsel a taper. The FDA is betting this generation of the product does less harm than the last one. The people who lived through what the last one did to a middle school bathroom get to be skeptical of the bet.